Aurinia Pharmaceuticals Archives - Page 2 of 2

Tag: Aurinia Pharmaceuticals

Aurinia Completes NDA and Requests Priority Review of Voclosoporin by FDA for Lupus Nephritis

May 28, 2020 The Lupus Research Alliance is pleased to share that Aurinia Pharmaceuticals Inc submitted a New Drug Application (NDA) to the U.S. FDA for voclosporin as a potential treatment for lupus nephritis with request for a priority review. Lupus nephritis is one of the most common complications of systemic lupus erythematosus, a serious […] Read More

Aurinia Moves Voclosporin Closer to FDA Approval for Lupus Nephritis

March 16, 2020 The Lupus Research Alliance is pleased to share an announcement from Aurinia Pharmaceuticals that moves its potential treatment for lupus nephritis, voclosporin, one step closer to approval by the U.S. Food and Drug Administration (FDA). The Company announced in a press release March 16 that it has started a Rolling Submission of […] Read More

Lupus Research Alliance Applauds Phase III Trial Results for Potential Lupus Nephritis Treatment

December 4, 2019 The Lupus Research Alliance congratulates Aurinia Pharmaceuticals on achieving the first positive Phase III trial results for an urgently needed treatment for lupus nephritis. The company’s investigational drug voclosporin showed positive effectiveness and good safety for treating lupus nephritis in combination with standard therapy. “Lupus nephritis is one of the most common […] Read More